SC Health Corp Stock: price and insider trades · United States
SC Health Corp: what insiders have been doing
SC Health Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). SC Health Corp has had no insider filing for more than a year; the last one goes back to 13 August 2021.
Since 2020, the database holds no purchases and 15 sales by insiders of the company.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
- 5,487,500 sharesOrdinary SharesSEC:0001140361-21-028218:0
- 3,400 shares@ US$10.750.7% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000131:0
- 10,000 shares@ US$10.752.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000131:1
- 100,000 shares@ US$10.3720.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000028:0
- 26,238 shares@ US$10.345.4% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000028:1
- 96,025 shares@ US$10.5020.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000022:0
- 100,000 shares@ US$10.4020.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000022:1
- 100,000 shares@ US$10.3620.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000022:2
- 34,933 shares@ US$10.647.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000003:0
- 7,154 shares@ US$10.581.5% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000003:1
- 5,150 shares@ US$10.531.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000003:2
- 246 shares@ US$10.500.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001076809-21-000003:3
- 82 shares@ US$10.1433.2% of flowClass A Ordinary SharesSEC:0001076809-20-000243:0
- 100 shares@ US$10.1541.2% of flowClass A Ordinary SharesSEC:0001076809-20-000212:0
- 62 shares@ US$10.2625.6% of flowClass A Ordinary Shares, Par Value $0.0001SEC:0001076809-20-000173:0
- 500,000 shares@ US$9.95100.0% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001062993-20-002212:0
16 of 16 declarations
About SC Health Corp
SC Health Corp is a US-listed company on the NYSE in the United States, but it is important to frame it correctly: historically, it functioned as a special purpose acquisition company (SPAC), not as a conventional operating healthcare business. The company was founded in 2018 and incorporated in the Cayman Islands, while its executive offices were located in Singapore at 108 Robinson Road. That structure reflected an original mandate to pursue healthcare-related opportunities, particularly in the Asia-Pacific region.
From a business-model standpoint, SC Health’s role was to raise public capital and identify a target company for a merger, share exchange, asset acquisition, or similar business combination. In other words, its value proposition was financial and strategic rather than operational. This is a key distinction for investors: there was no long-established portfolio of drugs, clinics, medical devices, or hospital services to analyze in the traditional sense. Instead, the investable thesis centered on deal execution, sponsor quality, governance, and the attractiveness of the target company selected for the combination.
Read moreShow less
In 2021, SC Health announced and later completed its business combination with Rockley Photonics, a silicon-photonics technology company focused on sensing platforms and health-and-wellness applications. That transaction materially changed the company’s profile and effectively moved the market story away from SC Health as a standalone SPAC toward the combined public company structure. As a result, any analysis of SC Health should be read through the lens of corporate transformation, rather than ongoing standalone operations.
For French-speaking investors in France, Belgium, and Switzerland, the most relevant competitive advantage SC Health offered was access to public markets and the ability to provide a faster route to listing for a healthcare or healthtech target than a traditional IPO. In SPAC structures, the quality of the eventual target is everything. The key questions are whether the business has defensible technology, a credible commercialization path, sufficient funding, and management capable of executing across multiple jurisdictions.
The company’s public filings and press releases also indicate an initial focus on innovative consumer health and wellness technologies, highlighting the kind of next-generation healthcare exposure management was seeking. Because SC Health transitioned through a business combination, it should not be treated as a mature healthcare operator with stable product lines, geographic footprints, or recurring revenue streams. Instead, it is best understood as a transaction vehicle that helped bring a healthtech platform to the NYSE.
In short, SC Health Corp was a Cayman-incorporated SPAC founded in 2018, headquartered operationally in Singapore, listed on the NYSE in the United States, and ultimately used as a conduit for a healthcare/technology business combination that reshaped its market identity.
